NCT00004474 is a Phase 3 clinical trial of Anti-thymocyte globulin in Aplastic Anemia, sponsored by Roswell Park Cancer Institute.

Who is sponsoring NCT00004474?

NCT00004474 is sponsored by Roswell Park Cancer Institute.

What drugs are being tested in NCT00004474?

Interventions in NCT00004474: Anti-thymocyte globulin, Cyclophosphamide, Bone marrow transplantation.

What condition does NCT00004474 study?

NCT00004474 studies Aplastic Anemia.

Is NCT00004474 still recruiting?

NCT00004474 is currently completed. Last updated 9 March 2018.

Last reviewed 2018-03-09 · How we verify

NCT00004474

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Phase III Randomized Study of Cyclophosphamide With or Without Antithymocyte Globulin Before Bone Marrow Transplantation in Patients With Aplastic Anemia

Completed Phase 3 Last updated 9 March 2018

What this trial tests

Phase 3 trial testing Anti-thymocyte globulin in Aplastic Anemia in 224 participants. Completed in 1 August 2007.

Timeline

1 September 1998

Primary endpoint
1 August 2007

1 August 2007

Quick facts

Lead sponsor	Roswell Park Cancer Institute
Phase	Phase 3
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Primary purpose	treatment
Enrollment	224
Start date	1 September 1998
Primary completion	1 August 2007
Estimated completion	1 August 2007
Sites	4 locations across United States

Drugs / interventions tested

Anti-thymocyte globulin
Cyclophosphamide (cyclophosphamide) — full drug profile →
Bone marrow transplantation

Conditions studied

Aplastic Anemia — all drugs for Aplastic Anemia →

Sponsor

Roswell Park Cancer Institute

Who can join

Under 59, any sex, with Aplastic Anemia. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Graft failure, graft versus host disease, and survival
Time frame: Measured at Day 100, Month 6, and Year 1 post-transplant

Sponsor's own description

OBJECTIVES: I. Compare outcome, including graft failure, graft versus host disease, and survival of HLA-identical sibling bone marrow transplants for aplastic anemia using cyclophosphamide with or without antithymocyte globulin as a conditioning regimen.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Anti-thymocyte globulin

Trials testing the same drug.

NCT04945096 — Outcomes of Patients After Allo-HSCT With Decitabine and NAC · Phase 3 · unknown
NCT02162420 — Hematopoietic Stem Cell Transplant for Dyskeratosis Congenita or Severe Aplastic Anemia · NA · completed
NCT00882895 — Tandem Stem Cell Transplantation for Non-Hodgkin's Lymphoma · Phase 2 · active not recruiting
NCT00489281 — Non-Myeloablative Bone Marrow Transplant for Patients With Sickle Cell Anemia and Other Blood Disorders · Phase 2 · terminated

Other recruiting trials for Aplastic Anemia

Currently open trials in the same condition.

NCT07101770 — A Prediction Model in Pregnant Women With Aplastic Anemia · recruiting
NCT06752694 — Ruxolitinib Based GVHD Prophylaxis Regimen Before, During, and After Hematopoietic Cell Transplantation in Older Adult P · Phase 2 · recruiting
NCT06936930 — Reproductive and Mental Health of Patients With Aplastic Anemia · recruiting
NCT06689800 — Let's Get REAL: Family Health Communication Tool in Pediatric Stem Cell Transplant and Cellular Therapy · NA · recruiting
NCT06613880 — Standard Immunosuppressive Therapy Combined With Romiplostim N01 as First-line Treatment for Severe Aplastic Anemia · Phase 2 · recruiting

Other Roswell Park Cancer Institute trials

Trials by the same sponsor.

NCT07489287 — GB-5267 for the Treatment Platinum-Resistant Ovarian, Peritoneal, or Fallopian Tube Cancer · Phase 1 · not yet recruiting
NCT06943664 — Photoimmunotherapy With ASP-1929 and Cemiplimab for the Treatment of Refractory, Inoperable, and Metastatic Stage IIIB-I · Phase 2 · not yet recruiting
NCT06827054 — Psilocybin With Psychotherapy for Improving Chronic Pain in Cancer Patients Requiring Opioids · Phase 2 · not yet recruiting
NCT06334016 — Evaluating the Delivery and Effects of THC Vaping Liquids in the Bloodstream · EARLY_PHASE1 · not yet recruiting
NCT06670976 — Propranolol Plus Standard Radiation Therapy Before Surgery for the Treatment of Patients With Soft Tissue Sarcoma · Phase 1 · withdrawn

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00004474 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Roswell Park Cancer Institute
Last refreshed: 9 March 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00004474.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing